View ValuationLinical 将来の成長Future 基準チェック /06現在、 Linicalの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長24.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • May 17Consensus EPS estimates increase by 96%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥12.3b to JP¥12.6b. EPS estimate increased from JP¥13.60 to JP¥26.60 per share. Net income forecast to shrink 22% next year vs 28% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥500 unchanged from last update. Share price was steady at JP¥408 over the past week.お知らせ • May 16+ 1 more updateLinical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025Linical Co., Ltd. provided forecast of consolidated financial result for the year ending March 31, 2025. For the period, the company expected Net sales of JPY 12,669 million, Operating income of JPY 1,009 million, Profit attributable to owners of parent of JPY 697 million, and Net income per share of JPY 30.86.Major Estimate Revision • Apr 18Consensus EPS estimates have been upgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥11.9b to JP¥12.3b. EPS estimate increased from JP¥0.00 per share to JP¥13.60 per share. Life Sciences industry in Japan expected to see average net income growth of 26% next year. Consensus price target of JP¥500 unchanged from last update. Share price rose 2.6% to JP¥399 over the past week.Major Estimate Revision • Nov 21Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.3b to JP¥13.0b. EPS estimate also fell from JP¥48.70 per share to JP¥40.70 per share. Net income forecast to grow 43% next year vs 13% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,200 to JP¥1,000. Share price fell 6.1% to JP¥557 over the past week.Major Estimate Revision • Sep 06Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.6b to JP¥13.3b. EPS estimate also fell from JP¥55.30 per share to JP¥48.70 per share. Net income forecast to grow 24% next year vs 5.2% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,400 to JP¥1,200. Share price was steady at JP¥708 over the past week.お知らせ • Dec 27+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023Linical Co., Ltd. provided earnings guidance for the year ending March 2023. For the year ending March 2023, the company expects net sales of JPY 12,440 million, operating profit of JPY 1,224 million and net profit of JPY 871 million.すべての更新を表示Recent updatesReported Earnings • May 20Full year 2026 earnings released: JP¥147 loss per share (vs JP¥23.86 loss in FY 2025)Full year 2026 results: JP¥147 loss per share (further deteriorated from JP¥23.86 loss in FY 2025). Revenue: JP¥8.67b (down 17% from FY 2025). Net loss: JP¥3.33b (loss widened JP¥2.79b from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.お知らせ • May 15Linical Co., Ltd., Annual General Meeting, Jun 23, 2026Linical Co., Ltd., Annual General Meeting, Jun 23, 2026.Buy Or Sell Opportunity • May 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to JP¥240. The fair value is estimated to be JP¥303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Feb 14Third quarter 2026 earnings released: JP¥27.63 loss per share (vs JP¥1.63 loss in 3Q 2025)Third quarter 2026 results: JP¥27.63 loss per share (further deteriorated from JP¥1.63 loss in 3Q 2025). Revenue: JP¥1.98b (down 22% from 3Q 2025). Net loss: JP¥624.0m (loss widened JP¥587.1m from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.分析記事 • Jan 09Linical's (TSE:2183) Dividend Will Be ¥16.00Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th of June. This...お知らせ • Jan 08Linical Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026Linical Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026分析記事 • Dec 01Linical's (TSE:2183) Dividend Will Be ¥16.00The board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th...New Risk • Nov 21New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 5.3% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 40% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥6.80b market cap, or US$43.3m).Reported Earnings • Nov 18Second quarter 2026 earnings released: JP¥33.21 loss per share (vs JP¥8.77 loss in 2Q 2025)Second quarter 2026 results: JP¥33.21 loss per share (further deteriorated from JP¥8.77 loss in 2Q 2025). Revenue: JP¥2.23b (down 11% from 2Q 2025). Net loss: JP¥750.2m (loss widened 279% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.分析記事 • Nov 17Linical's (TSE:2183) Dividend Will Be ¥16.00The board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th...Declared Dividend • Nov 17Dividend of JP¥16.00 announcedDividend of JP¥16.00 is the same as last year. Ex-date: 30th March 2026 Payment date: 11th June 2026 Dividend yield will be 5.2%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 8.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Sep 30Linical Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025Linical Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥7.79 loss per share (vs JP¥3.63 loss in 1Q 2025)First quarter 2026 results: JP¥7.79 loss per share (further deteriorated from JP¥3.63 loss in 1Q 2025). Revenue: JP¥2.63b (down 10% from 1Q 2025). Net loss: JP¥176.0m (loss widened 115% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.お知らせ • Jul 02Linical Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025Linical Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • Jun 30Full year 2025 earnings released: JP¥23.86 loss per share (vs JP¥14.97 profit in FY 2024)Full year 2025 results: JP¥23.86 loss per share (down from JP¥14.97 profit in FY 2024). Revenue: JP¥10.4b (down 15% from FY 2024). Net loss: JP¥539.0m (down 260% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.Reported Earnings • May 21Full year 2025 earnings released: JP¥23.86 loss per share (vs JP¥14.97 profit in FY 2024)Full year 2025 results: JP¥23.86 loss per share (down from JP¥14.97 profit in FY 2024). Revenue: JP¥10.4b (down 15% from FY 2024). Net loss: JP¥539.0m (down 260% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • May 15Linical Co., Ltd., Annual General Meeting, Jun 25, 2025Linical Co., Ltd., Annual General Meeting, Jun 25, 2025.お知らせ • Apr 05Linical Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Linical Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025Upcoming Dividend • Mar 21Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 12 June 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 4.7%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.8%).分析記事 • Feb 20Linical's (TSE:2183) Upcoming Dividend Will Be Larger Than Last Year'sLinical Co., Ltd. ( TSE:2183 ) will increase its dividend from last year's comparable payment on the 12th of June to...Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥1.59 loss per share (vs JP¥3.32 profit in 3Q 2024)Third quarter 2025 results: JP¥1.59 loss per share (down from JP¥3.32 profit in 3Q 2024). Revenue: JP¥2.53b (down 21% from 3Q 2024). Net loss: JP¥36.0m (down 148% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.分析記事 • Jan 03Linical (TSE:2183) Is Increasing Its Dividend To ¥16.00Linical Co., Ltd.'s ( TSE:2183 ) dividend will be increasing from last year's payment of the same period to ¥16.00 on...お知らせ • Jan 03Linical Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025Linical Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025分析記事 • Dec 01Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last YearLinical Co., Ltd.'s ( TSE:2183 ) dividend will be increasing from last year's payment of the same period to ¥16.00 on...分析記事 • Nov 17Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last YearThe board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will be paying its dividend of ¥16.00 on the 12th of...Declared Dividend • Nov 16Dividend of JP¥16.00 announcedShareholders will receive a dividend of JP¥16.00. Ex-date: 28th March 2025 Payment date: 12th June 2025 Dividend yield will be 4.7%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is not covered by earnings (134% earnings payout ratio). However, it is well covered by cash flows (35% cash payout ratio). The dividend has increased by an average of 8.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 49% to bring the payout ratio under control. EPS is expected to grow by 90% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.お知らせ • Sep 28Linical Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024Linical Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 16First quarter 2025 earnings released: JP¥3.63 loss per share (vs JP¥0.13 profit in 1Q 2024)First quarter 2025 results: JP¥3.63 loss per share (down from JP¥0.13 profit in 1Q 2024). Revenue: JP¥2.93b (down 5.1% from 1Q 2024). Net loss: JP¥82.0m (down JP¥85.0m from profit in 1Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 23% per year.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥340, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Life Sciences industry in Asia. Total loss to shareholders of 58% over the past three years.Buy Or Sell Opportunity • Jul 24Now 23% undervaluedOver the last 90 days, the stock has risen 3.9% to JP¥424. The fair value is estimated to be JP¥547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 4.6%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.お知らせ • Jul 07Linical Co., Ltd. to Report Q1, 2025 Results on Aug 14, 2024Linical Co., Ltd. announced that they will report Q1, 2025 results on Aug 14, 2024Buy Or Sell Opportunity • Jul 05Now 21% undervaluedOver the last 90 days, the stock has risen 15% to JP¥441. The fair value is estimated to be JP¥556, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 4.6%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.分析記事 • May 22There May Be Some Bright Spots In Linical's (TSE:2183) EarningsThe market for Linical Co., Ltd.'s ( TSE:2183 ) shares didn't move much after it posted weak earnings recently. We did...Reported Earnings • May 19Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥14.97 (down from JP¥44.45 in FY 2023). Revenue: JP¥12.3b (down 1.7% from FY 2023). Net income: JP¥338.0m (down 66% from FY 2023). Profit margin: 2.7% (down from 8.0% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • May 17Consensus EPS estimates increase by 96%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥12.3b to JP¥12.6b. EPS estimate increased from JP¥13.60 to JP¥26.60 per share. Net income forecast to shrink 22% next year vs 28% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥500 unchanged from last update. Share price was steady at JP¥408 over the past week.お知らせ • May 17Linical Co., Ltd., Annual General Meeting, Jun 26, 2024Linical Co., Ltd., Annual General Meeting, Jun 26, 2024.お知らせ • May 16+ 1 more updateLinical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025Linical Co., Ltd. provided forecast of consolidated financial result for the year ending March 31, 2025. For the period, the company expected Net sales of JPY 12,669 million, Operating income of JPY 1,009 million, Profit attributable to owners of parent of JPY 697 million, and Net income per share of JPY 30.86.Major Estimate Revision • Apr 18Consensus EPS estimates have been upgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥11.9b to JP¥12.3b. EPS estimate increased from JP¥0.00 per share to JP¥13.60 per share. Life Sciences industry in Japan expected to see average net income growth of 26% next year. Consensus price target of JP¥500 unchanged from last update. Share price rose 2.6% to JP¥399 over the past week.お知らせ • Apr 03Linical Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024Linical Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024Upcoming Dividend • Mar 21Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 10 June 2024. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (2.3%).分析記事 • Mar 08Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% PoundingThe Linical Co., Ltd. ( TSE:2183 ) share price has fared very poorly over the last month, falling by a substantial 26...分析記事 • Feb 26Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last YearThe board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will be paying its dividend of ¥15.00 on the 10th of...Reported Earnings • Feb 16Third quarter 2024 earnings released: EPS: JP¥3.32 (vs JP¥4.83 in 3Q 2023)Third quarter 2024 results: EPS: JP¥3.32 (down from JP¥4.83 in 3Q 2023). Revenue: JP¥3.18b (down 4.3% from 3Q 2023). Net income: JP¥75.0m (down 31% from 3Q 2023). Profit margin: 2.4% (down from 3.3% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Life Sciences industry in Japan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Dec 24Linical Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024Linical Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024Major Estimate Revision • Nov 21Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.3b to JP¥13.0b. EPS estimate also fell from JP¥48.70 per share to JP¥40.70 per share. Net income forecast to grow 43% next year vs 13% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,200 to JP¥1,000. Share price fell 6.1% to JP¥557 over the past week.New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.6% Last year net profit margin: 8.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (JP¥12.3b market cap, or US$82.4m).お知らせ • Oct 05Linical Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023Linical Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.0b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Major Estimate Revision • Sep 06Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.6b to JP¥13.3b. EPS estimate also fell from JP¥55.30 per share to JP¥48.70 per share. Net income forecast to grow 24% next year vs 5.2% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,400 to JP¥1,200. Share price was steady at JP¥708 over the past week.New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 15First quarter 2024 earnings released: EPS: JP¥0.13 (vs JP¥3.37 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.13 (down from JP¥3.37 in 1Q 2023). Revenue: JP¥3.08b (up 7.5% from 1Q 2023). Net income: JP¥3.00m (down 96% from 1Q 2023). Profit margin: 0.1% (down from 2.6% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Life Sciences industry in Japan. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Jul 13Linical Co., Ltd. to Report Q1, 2024 Results on Aug 14, 2023Linical Co., Ltd. announced that they will report Q1, 2024 results on Aug 14, 2023Buying Opportunity • Jun 23Now 22% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be JP¥1,021, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥827, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 6.3% over the past three years.Reported Earnings • May 18Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥44.45 (up from JP¥34.98 in FY 2022). Revenue: JP¥12.5b (up 8.3% from FY 2022). Net income: JP¥1.00b (up 27% from FY 2022). Profit margin: 8.0% (up from 6.8% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • May 16Linical Co., Ltd., Annual General Meeting, Jun 22, 2023Linical Co., Ltd., Annual General Meeting, Jun 22, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per share at 2.0% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 09 June 2023. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: JP¥4.83 (vs JP¥12.04 in 3Q 2022)Third quarter 2023 results: EPS: JP¥4.83 (down from JP¥12.04 in 3Q 2022). Revenue: JP¥3.33b (up 7.6% from 3Q 2022). Net income: JP¥109.0m (down 60% from 3Q 2022). Profit margin: 3.3% (down from 8.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Feb 15+ 1 more updateLinical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023Linical Co., Ltd. provides dividend guidance for the full year ending March 31, 2023. The company expects to pay JPY 14.00 against JPY 14.00 reported a year ago.お知らせ • Dec 29Linical Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023Linical Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023お知らせ • Dec 27+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023Linical Co., Ltd. provided earnings guidance for the year ending March 2023. For the year ending March 2023, the company expects net sales of JPY 12,440 million, operating profit of JPY 1,224 million and net profit of JPY 871 million.Price Target Changed • Nov 16Price target increased to JP¥1,400Up from JP¥1,300, the current price target is provided by 1 analyst. New target price is 94% above last closing price of JP¥721. Stock is down 22% over the past year. The company is forecast to post earnings per share of JP¥38.50 for next year compared to JP¥34.98 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Outside Independent Director Akio Osawa was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 15Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023Linical Co., Ltd. provided Consolidated Earnings Guidance for the year ending March 31, 2023. For the year, company expects Net sales to be JPY 12,440 million, Operating income to be JPY 1,224 million, Profit attributable to owners of parent to be JPY 871 million and Net income per share to be JPY 38.56.お知らせ • Nov 02Linical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022Linical Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥3.37 (vs JP¥2.97 in 1Q 2022)First quarter 2023 results: EPS: JP¥3.37 (up from JP¥2.97 in 1Q 2022). Revenue: JP¥2.87b (up 3.0% from 1Q 2022). Net income: JP¥76.0m (up 13% from 1Q 2022). Profit margin: 2.6% (up from 2.4% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 12%, compared to a 16% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Aug 13+ 1 more updateLinical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Linical Co., Ltd. provided dividend guidance of JPY 14 per share for the fiscal year ending March 31, 2023 compared to JPY 14 per share a year ago.お知らせ • Jul 17Linical Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022Linical Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022Major Estimate Revision • May 26Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from JP¥12.0b to JP¥12.8b. EPS estimate increased from JP¥38.50 to JP¥44.30 per share. Net income forecast to grow 27% next year vs 36% growth forecast for Life Sciences industry in Japan. Consensus price target up from JP¥1,300 to JP¥1,400. Share price rose 5.9% to JP¥855 over the past week.Reported Earnings • May 20Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥34.98 (up from JP¥23.86 in FY 2021). Revenue: JP¥11.6b (up 12% from FY 2021). Net income: JP¥790.0m (up 47% from FY 2021). Profit margin: 6.8% (up from 5.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 36%. Over the next year, revenue is forecast to grow 3.9% compared to a 3.6% decline forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • May 18+ 2 more updatesLinical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023Linical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales to be JPY 12,440 million. Operating income to be JPY 1,224 million. Profit attributable to owners of parent to be JPY 871 million. Net income per share to be JPY 38.56.お知らせ • May 17Linical Co., Ltd., Annual General Meeting, Jun 23, 2022Linical Co., Ltd., Annual General Meeting, Jun 23, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Audit & Supervisory Board Member Yoshimitsu Ando was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Mar 31Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from JP¥28.80 to JP¥25.70 per share. Revenue forecast steady at JP¥11.5b. Net income forecast to shrink 12% next year vs 30% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥1,300 unchanged from last update. Share price rose 4.6% to JP¥913 over the past week.Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to JP¥899, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 41x in the Life Sciences industry in Asia. Total loss to shareholders of 31% over the past three years.Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 10 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.3%).Reported Earnings • Feb 17Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: JP¥12.04 (up from JP¥7.53 in 3Q 2021). Revenue: JP¥3.09b (up 21% from 3Q 2021). Net income: JP¥272.0m (up 60% from 3Q 2021). Profit margin: 8.8% (up from 6.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.3%. Earnings per share (EPS) also surpassed analyst estimates by 126%. Over the next year, revenue is forecast to grow 3.9% while the industry in Japan is not expected to grow. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Feb 16+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022Linical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expects net sales to be JPY 10,700 million and operating income to be JPY 683 million.お知らせ • Feb 03Linical Co., Ltd. to Report Q3, 2022 Results on Feb 14, 2022Linical Co., Ltd. announced that they will report Q3, 2022 results on Feb 14, 2022Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS JP¥8.19 (vs JP¥8.24 in 2Q 2021)The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2022 results: Revenue: JP¥2.74b (up 7.1% from 2Q 2021). Net income: JP¥185.0m (flat on 2Q 2021). Profit margin: 6.8% (down from 7.3% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 13% per year.Reported Earnings • Aug 13First quarter 2022 earnings released: EPS JP¥2.97 (vs JP¥8.81 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥2.78b (up 15% from 1Q 2021). Net income: JP¥67.0m (up JP¥266.0m from 1Q 2021). Profit margin: 2.4% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥979, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 83x in the Life Sciences industry in Asia. Total loss to shareholders of 54% over the past three years.Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥23.86 (vs JP¥21.34 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥10.3b (down 6.0% from FY 2020). Net income: JP¥539.0m (up 12% from FY 2020). Profit margin: 5.2% (up from 4.4% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.4%).Major Estimate Revision • Feb 19Analysts lower EPS estimates to JP¥10.60The 2021 consensus revenue estimate was lowered from JP¥10.4b to JP¥10.1b. Earning per share (EPS) estimate was also lowered from JP¥12.00 to JP¥10.60 for the same period. Net income is expected to grow by 62% next year compared to 27% growth forecast for the Life Sciences industry in Japan. The consensus price target was lowered from JP¥900 to JP¥800. Share price stayed mostly flat at JP¥762 over the past week.Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS JP¥7.53 (vs JP¥7.44 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: JP¥2.55b (down 9.4% from 3Q 2020). Net income: JP¥170.0m (up 1.2% from 3Q 2020). Profit margin: 6.7% (up from 6.0% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Feb 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 4.1%. Earnings per share (EPS) also missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 6.5%, compared to a 18% growth forecast for the Life Sciences industry in Japan.お知らせ • Jan 08Linical Co., Ltd. to Report Q3, 2021 Results on Feb 12, 2021Linical Co., Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to JP¥834, the stock is trading at a trailing P/E ratio of 78.8x, up from the previous P/E ratio of 66.7x. This compares to an average P/E of 49x in the Life Sciences industry in Japan. Total return to shareholders over the past three years is a loss of 46%. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Linical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:2183 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20268,665-3,329-1,643-1,611N/A12/31/20259,319-1,773N/AN/AN/A9/30/20259,870-1,186-1,024-1,016N/A6/30/202510,137-634N/AN/AN/A3/31/202510,437-539587595N/A12/31/202411,014-232N/AN/AN/A9/30/202411,669-120940975N/A6/30/202412,151253N/AN/AN/A3/31/202412,3073381,0331,065N/A12/31/202312,518680N/AN/AN/A9/30/202312,6607141,8051,811N/A6/30/202312,730931N/AN/AN/A3/31/202312,5161,0041,8261,839N/A12/31/202212,188843N/AN/AN/A9/30/202211,9531,0061,4121,454N/A6/30/202211,639799N/AN/AN/A3/31/202211,5557901,5851,631N/A12/31/202111,360906N/AN/AN/A9/30/202110,8208041,2891,343N/A6/30/202110,639805N/AN/AN/A3/31/202110,279539-4523N/A12/31/202010,262241N/AN/AN/A9/30/202010,52723961127N/A6/30/202010,679268N/AN/AN/A3/31/202010,9354821,0611,192N/A12/31/201910,944508N/AN/AN/A9/30/201911,090409N/A201N/A6/30/201911,234541N/AN/AN/A3/31/201911,313568N/A-796N/A12/31/201810,975853N/AN/AN/A9/30/201810,4061,147N/A515N/A6/30/20189,7361,177N/AN/AN/A3/31/20189,1131,295N/A1,360N/A12/31/20178,8701,281N/AN/AN/A9/30/20178,6451,237N/A2,133N/A6/30/20178,5411,381N/AN/AN/A3/31/20178,3551,447N/A2,291N/A12/31/20168,1311,375N/AN/AN/A9/30/20167,9161,331N/A1,173N/A6/30/20167,8911,368N/AN/AN/A3/31/20167,6661,330N/A1,817N/A12/31/20157,4201,154N/AN/AN/A9/30/20156,6441,015N/A1,775N/A6/30/20155,549579N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2183の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2183の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2183の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2183の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2183の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2183の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:28終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Linical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Masao YoshidaIchiyoshi Research Institute Inc.Michael NewmanMacquarie ResearchYasunori HiromotoMarusan Securities Co. Ltd.1 その他のアナリストを表示
Major Estimate Revision • May 17Consensus EPS estimates increase by 96%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥12.3b to JP¥12.6b. EPS estimate increased from JP¥13.60 to JP¥26.60 per share. Net income forecast to shrink 22% next year vs 28% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥500 unchanged from last update. Share price was steady at JP¥408 over the past week.
お知らせ • May 16+ 1 more updateLinical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025Linical Co., Ltd. provided forecast of consolidated financial result for the year ending March 31, 2025. For the period, the company expected Net sales of JPY 12,669 million, Operating income of JPY 1,009 million, Profit attributable to owners of parent of JPY 697 million, and Net income per share of JPY 30.86.
Major Estimate Revision • Apr 18Consensus EPS estimates have been upgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥11.9b to JP¥12.3b. EPS estimate increased from JP¥0.00 per share to JP¥13.60 per share. Life Sciences industry in Japan expected to see average net income growth of 26% next year. Consensus price target of JP¥500 unchanged from last update. Share price rose 2.6% to JP¥399 over the past week.
Major Estimate Revision • Nov 21Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.3b to JP¥13.0b. EPS estimate also fell from JP¥48.70 per share to JP¥40.70 per share. Net income forecast to grow 43% next year vs 13% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,200 to JP¥1,000. Share price fell 6.1% to JP¥557 over the past week.
Major Estimate Revision • Sep 06Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.6b to JP¥13.3b. EPS estimate also fell from JP¥55.30 per share to JP¥48.70 per share. Net income forecast to grow 24% next year vs 5.2% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,400 to JP¥1,200. Share price was steady at JP¥708 over the past week.
お知らせ • Dec 27+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023Linical Co., Ltd. provided earnings guidance for the year ending March 2023. For the year ending March 2023, the company expects net sales of JPY 12,440 million, operating profit of JPY 1,224 million and net profit of JPY 871 million.
Reported Earnings • May 20Full year 2026 earnings released: JP¥147 loss per share (vs JP¥23.86 loss in FY 2025)Full year 2026 results: JP¥147 loss per share (further deteriorated from JP¥23.86 loss in FY 2025). Revenue: JP¥8.67b (down 17% from FY 2025). Net loss: JP¥3.33b (loss widened JP¥2.79b from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
お知らせ • May 15Linical Co., Ltd., Annual General Meeting, Jun 23, 2026Linical Co., Ltd., Annual General Meeting, Jun 23, 2026.
Buy Or Sell Opportunity • May 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to JP¥240. The fair value is estimated to be JP¥303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.8% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Feb 14Third quarter 2026 earnings released: JP¥27.63 loss per share (vs JP¥1.63 loss in 3Q 2025)Third quarter 2026 results: JP¥27.63 loss per share (further deteriorated from JP¥1.63 loss in 3Q 2025). Revenue: JP¥1.98b (down 22% from 3Q 2025). Net loss: JP¥624.0m (loss widened JP¥587.1m from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
分析記事 • Jan 09Linical's (TSE:2183) Dividend Will Be ¥16.00Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th of June. This...
お知らせ • Jan 08Linical Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026Linical Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
分析記事 • Dec 01Linical's (TSE:2183) Dividend Will Be ¥16.00The board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th...
New Risk • Nov 21New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 5.3% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 40% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥6.80b market cap, or US$43.3m).
Reported Earnings • Nov 18Second quarter 2026 earnings released: JP¥33.21 loss per share (vs JP¥8.77 loss in 2Q 2025)Second quarter 2026 results: JP¥33.21 loss per share (further deteriorated from JP¥8.77 loss in 2Q 2025). Revenue: JP¥2.23b (down 11% from 2Q 2025). Net loss: JP¥750.2m (loss widened 279% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 17Linical's (TSE:2183) Dividend Will Be ¥16.00The board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will pay a dividend of ¥16.00 per share on the 11th...
Declared Dividend • Nov 17Dividend of JP¥16.00 announcedDividend of JP¥16.00 is the same as last year. Ex-date: 30th March 2026 Payment date: 11th June 2026 Dividend yield will be 5.2%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 8.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Sep 30Linical Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025Linical Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥7.79 loss per share (vs JP¥3.63 loss in 1Q 2025)First quarter 2026 results: JP¥7.79 loss per share (further deteriorated from JP¥3.63 loss in 1Q 2025). Revenue: JP¥2.63b (down 10% from 1Q 2025). Net loss: JP¥176.0m (loss widened 115% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 02Linical Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025Linical Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • Jun 30Full year 2025 earnings released: JP¥23.86 loss per share (vs JP¥14.97 profit in FY 2024)Full year 2025 results: JP¥23.86 loss per share (down from JP¥14.97 profit in FY 2024). Revenue: JP¥10.4b (down 15% from FY 2024). Net loss: JP¥539.0m (down 260% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 21Full year 2025 earnings released: JP¥23.86 loss per share (vs JP¥14.97 profit in FY 2024)Full year 2025 results: JP¥23.86 loss per share (down from JP¥14.97 profit in FY 2024). Revenue: JP¥10.4b (down 15% from FY 2024). Net loss: JP¥539.0m (down 260% from profit in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • May 15Linical Co., Ltd., Annual General Meeting, Jun 25, 2025Linical Co., Ltd., Annual General Meeting, Jun 25, 2025.
お知らせ • Apr 05Linical Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Linical Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025
Upcoming Dividend • Mar 21Upcoming dividend of JP¥16.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 12 June 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 4.7%. Within top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (2.8%).
分析記事 • Feb 20Linical's (TSE:2183) Upcoming Dividend Will Be Larger Than Last Year'sLinical Co., Ltd. ( TSE:2183 ) will increase its dividend from last year's comparable payment on the 12th of June to...
Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥1.59 loss per share (vs JP¥3.32 profit in 3Q 2024)Third quarter 2025 results: JP¥1.59 loss per share (down from JP¥3.32 profit in 3Q 2024). Revenue: JP¥2.53b (down 21% from 3Q 2024). Net loss: JP¥36.0m (down 148% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
分析記事 • Jan 03Linical (TSE:2183) Is Increasing Its Dividend To ¥16.00Linical Co., Ltd.'s ( TSE:2183 ) dividend will be increasing from last year's payment of the same period to ¥16.00 on...
お知らせ • Jan 03Linical Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025Linical Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025
分析記事 • Dec 01Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last YearLinical Co., Ltd.'s ( TSE:2183 ) dividend will be increasing from last year's payment of the same period to ¥16.00 on...
分析記事 • Nov 17Linical's (TSE:2183) Shareholders Will Receive A Bigger Dividend Than Last YearThe board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will be paying its dividend of ¥16.00 on the 12th of...
Declared Dividend • Nov 16Dividend of JP¥16.00 announcedShareholders will receive a dividend of JP¥16.00. Ex-date: 28th March 2025 Payment date: 12th June 2025 Dividend yield will be 4.7%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is not covered by earnings (134% earnings payout ratio). However, it is well covered by cash flows (35% cash payout ratio). The dividend has increased by an average of 8.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 49% to bring the payout ratio under control. EPS is expected to grow by 90% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
お知らせ • Sep 28Linical Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024Linical Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 16First quarter 2025 earnings released: JP¥3.63 loss per share (vs JP¥0.13 profit in 1Q 2024)First quarter 2025 results: JP¥3.63 loss per share (down from JP¥0.13 profit in 1Q 2024). Revenue: JP¥2.93b (down 5.1% from 1Q 2024). Net loss: JP¥82.0m (down JP¥85.0m from profit in 1Q 2024). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 23% per year.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥340, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Life Sciences industry in Asia. Total loss to shareholders of 58% over the past three years.
Buy Or Sell Opportunity • Jul 24Now 23% undervaluedOver the last 90 days, the stock has risen 3.9% to JP¥424. The fair value is estimated to be JP¥547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 4.6%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
お知らせ • Jul 07Linical Co., Ltd. to Report Q1, 2025 Results on Aug 14, 2024Linical Co., Ltd. announced that they will report Q1, 2025 results on Aug 14, 2024
Buy Or Sell Opportunity • Jul 05Now 21% undervaluedOver the last 90 days, the stock has risen 15% to JP¥441. The fair value is estimated to be JP¥556, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.6% over the last 3 years. Earnings per share has declined by 4.6%. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
分析記事 • May 22There May Be Some Bright Spots In Linical's (TSE:2183) EarningsThe market for Linical Co., Ltd.'s ( TSE:2183 ) shares didn't move much after it posted weak earnings recently. We did...
Reported Earnings • May 19Full year 2024 earnings: EPS exceeds analyst expectationsFull year 2024 results: EPS: JP¥14.97 (down from JP¥44.45 in FY 2023). Revenue: JP¥12.3b (down 1.7% from FY 2023). Net income: JP¥338.0m (down 66% from FY 2023). Profit margin: 2.7% (down from 8.0% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • May 17Consensus EPS estimates increase by 96%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from JP¥12.3b to JP¥12.6b. EPS estimate increased from JP¥13.60 to JP¥26.60 per share. Net income forecast to shrink 22% next year vs 28% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥500 unchanged from last update. Share price was steady at JP¥408 over the past week.
お知らせ • May 17Linical Co., Ltd., Annual General Meeting, Jun 26, 2024Linical Co., Ltd., Annual General Meeting, Jun 26, 2024.
お知らせ • May 16+ 1 more updateLinical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025Linical Co., Ltd. provided forecast of consolidated financial result for the year ending March 31, 2025. For the period, the company expected Net sales of JPY 12,669 million, Operating income of JPY 1,009 million, Profit attributable to owners of parent of JPY 697 million, and Net income per share of JPY 30.86.
Major Estimate Revision • Apr 18Consensus EPS estimates have been upgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from JP¥11.9b to JP¥12.3b. EPS estimate increased from JP¥0.00 per share to JP¥13.60 per share. Life Sciences industry in Japan expected to see average net income growth of 26% next year. Consensus price target of JP¥500 unchanged from last update. Share price rose 2.6% to JP¥399 over the past week.
お知らせ • Apr 03Linical Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024Linical Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024
Upcoming Dividend • Mar 21Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 10 June 2024. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (2.3%).
分析記事 • Mar 08Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% PoundingThe Linical Co., Ltd. ( TSE:2183 ) share price has fared very poorly over the last month, falling by a substantial 26...
分析記事 • Feb 26Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last YearThe board of Linical Co., Ltd. ( TSE:2183 ) has announced that it will be paying its dividend of ¥15.00 on the 10th of...
Reported Earnings • Feb 16Third quarter 2024 earnings released: EPS: JP¥3.32 (vs JP¥4.83 in 3Q 2023)Third quarter 2024 results: EPS: JP¥3.32 (down from JP¥4.83 in 3Q 2023). Revenue: JP¥3.18b (down 4.3% from 3Q 2023). Net income: JP¥75.0m (down 31% from 3Q 2023). Profit margin: 2.4% (down from 3.3% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Life Sciences industry in Japan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Dec 24Linical Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024Linical Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024
Major Estimate Revision • Nov 21Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.3b to JP¥13.0b. EPS estimate also fell from JP¥48.70 per share to JP¥40.70 per share. Net income forecast to grow 43% next year vs 13% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,200 to JP¥1,000. Share price fell 6.1% to JP¥557 over the past week.
New Risk • Nov 18New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.6% Last year net profit margin: 8.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (5.6% net profit margin). Market cap is less than US$100m (JP¥12.3b market cap, or US$82.4m).
お知らせ • Oct 05Linical Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023Linical Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023
New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.0b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Major Estimate Revision • Sep 06Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥13.6b to JP¥13.3b. EPS estimate also fell from JP¥55.30 per share to JP¥48.70 per share. Net income forecast to grow 24% next year vs 5.2% growth forecast for Life Sciences industry in Japan. Consensus price target down from JP¥1,400 to JP¥1,200. Share price was steady at JP¥708 over the past week.
New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 15First quarter 2024 earnings released: EPS: JP¥0.13 (vs JP¥3.37 in 1Q 2023)First quarter 2024 results: EPS: JP¥0.13 (down from JP¥3.37 in 1Q 2023). Revenue: JP¥3.08b (up 7.5% from 1Q 2023). Net income: JP¥3.00m (down 96% from 1Q 2023). Profit margin: 0.1% (down from 2.6% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Life Sciences industry in Japan. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Jul 13Linical Co., Ltd. to Report Q1, 2024 Results on Aug 14, 2023Linical Co., Ltd. announced that they will report Q1, 2024 results on Aug 14, 2023
Buying Opportunity • Jun 23Now 22% undervaluedOver the last 90 days, the stock is up 17%. The fair value is estimated to be JP¥1,021, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings is also forecast to grow by 18% per annum over the same time period.
Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥827, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 6.3% over the past three years.
Reported Earnings • May 18Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: JP¥44.45 (up from JP¥34.98 in FY 2022). Revenue: JP¥12.5b (up 8.3% from FY 2022). Net income: JP¥1.00b (up 27% from FY 2022). Profit margin: 8.0% (up from 6.8% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • May 16Linical Co., Ltd., Annual General Meeting, Jun 22, 2023Linical Co., Ltd., Annual General Meeting, Jun 22, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per share at 2.0% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 09 June 2023. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).
Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: JP¥4.83 (vs JP¥12.04 in 3Q 2022)Third quarter 2023 results: EPS: JP¥4.83 (down from JP¥12.04 in 3Q 2022). Revenue: JP¥3.33b (up 7.6% from 3Q 2022). Net income: JP¥109.0m (down 60% from 3Q 2022). Profit margin: 3.3% (down from 8.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Feb 15+ 1 more updateLinical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023Linical Co., Ltd. provides dividend guidance for the full year ending March 31, 2023. The company expects to pay JPY 14.00 against JPY 14.00 reported a year ago.
お知らせ • Dec 29Linical Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023Linical Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023
お知らせ • Dec 27+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023Linical Co., Ltd. provided earnings guidance for the year ending March 2023. For the year ending March 2023, the company expects net sales of JPY 12,440 million, operating profit of JPY 1,224 million and net profit of JPY 871 million.
Price Target Changed • Nov 16Price target increased to JP¥1,400Up from JP¥1,300, the current price target is provided by 1 analyst. New target price is 94% above last closing price of JP¥721. Stock is down 22% over the past year. The company is forecast to post earnings per share of JP¥38.50 for next year compared to JP¥34.98 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Outside Independent Director Akio Osawa was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 15Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023Linical Co., Ltd. provided Consolidated Earnings Guidance for the year ending March 31, 2023. For the year, company expects Net sales to be JPY 12,440 million, Operating income to be JPY 1,224 million, Profit attributable to owners of parent to be JPY 871 million and Net income per share to be JPY 38.56.
お知らせ • Nov 02Linical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022Linical Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥3.37 (vs JP¥2.97 in 1Q 2022)First quarter 2023 results: EPS: JP¥3.37 (up from JP¥2.97 in 1Q 2022). Revenue: JP¥2.87b (up 3.0% from 1Q 2022). Net income: JP¥76.0m (up 13% from 1Q 2022). Profit margin: 2.6% (up from 2.4% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 12%, compared to a 16% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Aug 13+ 1 more updateLinical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Linical Co., Ltd. provided dividend guidance of JPY 14 per share for the fiscal year ending March 31, 2023 compared to JPY 14 per share a year ago.
お知らせ • Jul 17Linical Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022Linical Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022
Major Estimate Revision • May 26Consensus EPS estimates increase by 15%The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from JP¥12.0b to JP¥12.8b. EPS estimate increased from JP¥38.50 to JP¥44.30 per share. Net income forecast to grow 27% next year vs 36% growth forecast for Life Sciences industry in Japan. Consensus price target up from JP¥1,300 to JP¥1,400. Share price rose 5.9% to JP¥855 over the past week.
Reported Earnings • May 20Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: EPS: JP¥34.98 (up from JP¥23.86 in FY 2021). Revenue: JP¥11.6b (up 12% from FY 2021). Net income: JP¥790.0m (up 47% from FY 2021). Profit margin: 6.8% (up from 5.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 36%. Over the next year, revenue is forecast to grow 3.9% compared to a 3.6% decline forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • May 18+ 2 more updatesLinical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023Linical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales to be JPY 12,440 million. Operating income to be JPY 1,224 million. Profit attributable to owners of parent to be JPY 871 million. Net income per share to be JPY 38.56.
お知らせ • May 17Linical Co., Ltd., Annual General Meeting, Jun 23, 2022Linical Co., Ltd., Annual General Meeting, Jun 23, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Audit & Supervisory Board Member Yoshimitsu Ando was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Mar 31Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from JP¥28.80 to JP¥25.70 per share. Revenue forecast steady at JP¥11.5b. Net income forecast to shrink 12% next year vs 30% growth forecast for Life Sciences industry in Japan . Consensus price target of JP¥1,300 unchanged from last update. Share price rose 4.6% to JP¥913 over the past week.
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improved over the past weekAfter last week's 20% share price gain to JP¥899, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 41x in the Life Sciences industry in Asia. Total loss to shareholders of 31% over the past three years.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 10 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.3%).
Reported Earnings • Feb 17Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: JP¥12.04 (up from JP¥7.53 in 3Q 2021). Revenue: JP¥3.09b (up 21% from 3Q 2021). Net income: JP¥272.0m (up 60% from 3Q 2021). Profit margin: 8.8% (up from 6.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.3%. Earnings per share (EPS) also surpassed analyst estimates by 126%. Over the next year, revenue is forecast to grow 3.9% while the industry in Japan is not expected to grow. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16+ 1 more updateLinical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022Linical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expects net sales to be JPY 10,700 million and operating income to be JPY 683 million.
お知らせ • Feb 03Linical Co., Ltd. to Report Q3, 2022 Results on Feb 14, 2022Linical Co., Ltd. announced that they will report Q3, 2022 results on Feb 14, 2022
Reported Earnings • Nov 15Second quarter 2022 earnings released: EPS JP¥8.19 (vs JP¥8.24 in 2Q 2021)The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2022 results: Revenue: JP¥2.74b (up 7.1% from 2Q 2021). Net income: JP¥185.0m (flat on 2Q 2021). Profit margin: 6.8% (down from 7.3% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 13% per year.
Reported Earnings • Aug 13First quarter 2022 earnings released: EPS JP¥2.97 (vs JP¥8.81 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥2.78b (up 15% from 1Q 2021). Net income: JP¥67.0m (up JP¥266.0m from 1Q 2021). Profit margin: 2.4% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥979, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 83x in the Life Sciences industry in Asia. Total loss to shareholders of 54% over the past three years.
Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥23.86 (vs JP¥21.34 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥10.3b (down 6.0% from FY 2020). Net income: JP¥539.0m (up 12% from FY 2020). Profit margin: 5.2% (up from 4.4% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥14.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.4%).
Major Estimate Revision • Feb 19Analysts lower EPS estimates to JP¥10.60The 2021 consensus revenue estimate was lowered from JP¥10.4b to JP¥10.1b. Earning per share (EPS) estimate was also lowered from JP¥12.00 to JP¥10.60 for the same period. Net income is expected to grow by 62% next year compared to 27% growth forecast for the Life Sciences industry in Japan. The consensus price target was lowered from JP¥900 to JP¥800. Share price stayed mostly flat at JP¥762 over the past week.
Reported Earnings • Feb 14Third quarter 2021 earnings released: EPS JP¥7.53 (vs JP¥7.44 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: JP¥2.55b (down 9.4% from 3Q 2020). Net income: JP¥170.0m (up 1.2% from 3Q 2020). Profit margin: 6.7% (up from 6.0% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Feb 14Revenue and earnings miss expectationsRevenue missed analyst estimates by 4.1%. Earnings per share (EPS) also missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 6.5%, compared to a 18% growth forecast for the Life Sciences industry in Japan.
お知らせ • Jan 08Linical Co., Ltd. to Report Q3, 2021 Results on Feb 12, 2021Linical Co., Ltd. announced that they will report Q3, 2021 results on Feb 12, 2021
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 18% share price gain to JP¥834, the stock is trading at a trailing P/E ratio of 78.8x, up from the previous P/E ratio of 66.7x. This compares to an average P/E of 49x in the Life Sciences industry in Japan. Total return to shareholders over the past three years is a loss of 46%.